Omalizumab
Omalizumab structure: (A) murine complementarity-determining region and (B) IgG1κ human framework | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | IgE Fc region |
| Clinical data | |
| Pronunciation | /ˌoʊməˈlɪzumæb/ OH-mə-LI-zoo-mab |
| Trade names | Xolair |
| Biosimilars | Omalizumab-igec, Omlyclo |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a603031 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Subcutaneous |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Elimination half-life | 26 days |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C6450H9916N1714O2023S38 |
| Molar mass | 145058.53 g·mol−1 |
| (what is this?) (verify) | |
Omalizumab, sold under the brand name Xolair among others, is an injectable medication to treat severe persistent allergic forms of asthma, nasal polyps, urticaria (hives), and immunoglobulin E-mediated food allergy.
Omalizumab is a recombinant DNA-derived humanized IgG1 monoclonal antibody which specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to the membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Its primary adverse effect is anaphylaxis.
In 1987, Tanox filed its first patent application on the anti-IgE drug candidate. Omalizumab was approved for medical use in the United States in June 2003, and authorized in the European Union in October 2005.